Is IKT or IMTX more undervalued in 2026?

CirclFi compares Inhibikase Therapeutics, Inc. (IKT) and Immatics N.V. (IMTX) using 13 institutional-grade valuation models. IKT has a Quality of Company score of 4.4/10 while IMTX scores 4.3/10.

Which is a better buy — IKT or IMTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IKT and IMTX valuations compare?

IKT at $1.75 and IMTX at $11.51 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IKT vs IMTX Valuation Comparison 2026 — Intrinsic Value Analysis

IKT

Biological Products, (No Diagnostic Substances)

Inhibikase Therapeutics, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$1.75

Last close

Models

9/13

Active

IMTX

Biological Products, (No Diagnostic Substances)

Immatics N.V.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$11.51

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	IKT Fair Value	IKT Upside	IMTX Fair Value	IMTX Upside
Bayesian DCF	Intrinsic	$0.66	-62.4%	$3.35	-70.9%
Earnings Power Value	Intrinsic	$0.34	-82.4%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.78	-55.4%	$0.84	-92.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IKT vs IMTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IKT vs IMTX — Which Stock Is More Undervalued?

IKT scores higher with a 4.4/10 quality rating vs IMTX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Inhibikase Therapeutics, Inc. (IKT) and Immatics N.V. (IMTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IKT currently trades at $1.75 with a QOC of 4.4/10, while IMTX trades at $11.51 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).